Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 114.30K | -- | 84.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 114.30K | -- | 84.20K |
| Cost of Revenue | 360.20K | -100.30K | 82.90K | 90.40K | 73.00K |
| Gross Profit | -360.20K | 100.30K | 31.30K | -90.40K | 11.20K |
| SG&A Expenses | 687.50K | 228.00K | 174.30K | 263.10K | 192.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.05M | 127.70K | 257.30K | 353.50K | 265.20K |
| Operating Income | -1.05M | -127.70K | -143.00K | -353.50K | -181.00K |
| Income Before Tax | -1.12M | -195.90K | -175.20K | -435.00K | -297.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.12M | -195.90K | -175.20K | -435.00K | -297.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.12M | -195.90K | -175.20K | -435.00K | -297.40K |
| EBIT | -1.05M | -127.70K | -143.00K | -353.50K | -181.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 66.11M | 65.51M | 66.11M | 65.47M | 64.94M |
| Average Diluted Shares Outstanding | 66.11M | 65.51M | 66.11M | 65.47M | 64.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |